AI-Powered Teleradiology FDA Cleared for Triage in Departments Swamped by COVID-19

By Conn Hastings at Medgadget

Nines, a teleradiology company based in Palo Alto, CA, recently received FDA clearance for their NinesAI medical device, which supports the automated radiological review of CT Head images for the possible presence of two time-critical, life-threatening indications: intracranial hemorrhage and mass effect. The technology can help radiologists in triaging cases. Nines is the first company to receive FDA clearance for AI technology that triages mass effect conditions.

Teleradiology is an increasingly vital service for healthcare providers, whereby radiological images are sent to a radiologist in a remote location for analysis. Moreover, AI has an emerging role in radiological diagnostics, and can provide a supportive role for radiologists in making their assessments.

All current customers and new customers who sign up with Nines before June 30, 2020 will get NinesAI for free. This access will allow Nines’ customers to assess, identify, and triage emergent conditions of intracranial hemorrhage and mass effect while in-house radiology departments are inundated, especially as some of these departments are overwhelmed by COVID-19 cases.

Medgadget had the opportunity to speak with David Stavens, CEO and co-founder of Nines, about the technology, and how the company is supporting quality care and radiologists in a time where hospitals and healthcare providers are resource-constrained.

Stavens has an interesting background in AI, having been involved in the world’s first robotic car “Stanley” as a co-founder of Stanford’s self-driving team, which became the foundation for Waymo, which was acquired by Google, itself part of Alphabet. He later co-founded and was CEO of online learning platform Udacity.

Conn Hastings, Medgadget: Please give us an overview of your background in AI.

David Stavens, Nines: I’ve loved computers since I was very young. I remember receiving my first Apple IIGS for Christmas in the late 1980s and learning to write computer software soon thereafter. It was unusual in those days for kids to be into computers and coding. As I got older, I recognized that computers and software were not only fun hobbies, but an exciting way to make a broader impact in the world.

I am drawn to important humanitarian problems and how they could be solved using computer technology. As co-founder and CEO of Udacity, Sebastian Thrun and I worked to use the web to make world class education and great jobs available to everyone in the world. Prior to that, we worked on building one of the first self-driving cars while at Stanford, which eventually became Waymo.

Self-driving technology has the potential to save many of the 40,000 lives lost every year in the U.S. due to traffic accidents, improving mobility for those with visual or neuromotor impairment, and making longer drives more pleasant for everyone. At Nines, we believe that radiology can be made even better for radiologists and patients using technology and we are excited to help bring that change about.

Medgadget: What inspired you to start Nines?

David Stavens: Our health is one of our most precious assets — a point made even more pronounced with the onset of COVID-19. But navigating the healthcare system is very complex, especially for those without insurance or those who do not live in an industrialized country. Access to timely, affordable,high quality care should be universal. At Nines, we believe that radiology can be made even better for radiologists and patients using technology and telehealth and we are excited to help bring that change about. The adoption of telehealth has only become more essential and prevalent in the time of COVID-19.

The use of medical imaging, such as MRI, CT and ultrasounds performed in healthcare facilities, has continued to rise, according to the Journal of American Medical Association in analyzing trends from seven integrated U.S. healthcare systems. These scans are not only increasing in number, but also in complexity — scans include more images and the images are of higher resolution.

According to the American College of Radiology, there is only one radiologist for every 10,000 Americans. To keep up, a typical radiologist must review one image every three to four seconds to meet workload demands in an 8 hour workday, according to a study from the Mayo Clinic. Each one of those images has the potential to show information that is critical in making a radiologic diagnosis that is used to direct patient care.

Nines is building world class technology to help. NinesAI is FDA-cleared and supports the automated radiological review of CT Head images for the possible presence of two time-critical, life-threatening indications – intracranial hemorrhage and mass effect – to aid radiologists in triaging cases and identify them more rapidly. In an emergency room late at night, an actionable report turned around quickly could give patients a reliable and speedy diagnosis and could calm worries about what is wrong.

Medgadget: Please give us an overview of the teleradiology services provided by Nines.

David Stavens: Nines is a teleradiology practice that pairs world-class radiologists with fantastic engineers and product managers to deliver high quality medical care accelerated by advanced technology.Hospitals and medical practices can choose Nines to read some volume of their radiology studies, for example on nights or weekends when they have fewer radiologists on call. With engineers and physicians side-by-side, technology and process improvements occur rapidly for the benefit of physicians, hospitals, medical practices, and patients.

For example, on average, a radiologist is interrupted about five times an hour, whether answering phone calls or coordinating with colleagues, which increases exam interpretation times, according to the Journal of Academic Radiology. At Nines, radiologists and engineers have worked together to develop the Nines Navigator™ worklist and the Nines Reading Assistant. These are administrative, non-medical device programs that aggregate clinical information and surface custom-built tools to improve radiologist focus. This includes listing relevant patient info and easier communication with hospital physicians interacting with the patients. Together with NinesAI, these tools assist Nines radiologists with providing timely, quality care.

Medgadget: How has the COVID-19 pandemic affected the services you offer and the clients you work with?

David Stavens: COVID-19 has placed unprecedented strain on all aspects of the U.S. healthcare system. We are offering in-house access to the NinesAI technology free of charge for new and existing Nines Radiology customers who sign up by June 30, 2020. Some healthcare providers are seeing early indications of a potential relationship between COVID-19 and an increase in the number of strokes in some younger patients. Stroke is one cause of intracranial hemorrhage and mass effect, the two conditions NinesAI detects. In addition, NinesAI improves radiology efficiency through triaging emerging studies, which we believe will be particularly helpful as radiologists are under strain at this time.

Medgadget: What are the strengths of AI in radiological analysis?

David Stavens: For emergent conditions of ICH and mass effect, time to intervention is critical. With intracranial hemorrhage for example, the 30-day mortality rate ranges from 35% to 52% with only 20% of survivors expected to have full functional recovery at 6 months, and approximately half of this mortality occurs within the first 24 hours.

Radiologists using NinesAI can be notified of a potential life-threatening finding in approximately 15 seconds after image acquisition is complete, meaning that potentially life-saving care can begin very quickly. The standard-of-care without AI is to read studies in the order in which they were received. We believe the role of artificial intelligence for radiology is to make radiologists’ lives better as an assistive technology that supports their service and prioritization of the patients who need care most urgently.

Medgadget: Please tell us about these most recently approved AI-powered teleradiology services.

David Stavens: At the end of April, we received unprecedented U.S. Food and Drug Administration clearance for artificial intelligence technology that triages intracranial hemorrhage and mass effect conditions on non-contrast CT scans of the head. Our NinesAI medical device supports the automated radiological review of images from these scans for the possible presence of these two time-critical, life-threatening indications to aid radiologists in triaging cases. We are proud to be the first company to receive FDA clearance for artificial intelligence technology that triages mass effect conditions and to our knowledge, the first company to receive simultaneous FDA clearance on multiple indications.

Original news can be found here.

Microfluidic Test for Viral Antibodies Takes Just 20 Minutes

By Conn Hastings
Researchers at Hokkaido University in Japan have developed a microfluidic test that can detect antibodies against a viral infection. So far, the test has been optimized to detect avian flu, but could be adapted to detect antibodies against the virus causing COVID-19. The device can provide a result in as little as 20 minutes and requires only 2 microliters of serum to run.

Antibody tests have been proposed as a way to determine how many people have been exposed to COVID-19, and may help us to understand how far the virus has spread. Given that many infected people are asymptomatic, they may never be recorded as infected, limiting our knowledge of infection levels and hampering the response to the pandemic.

However, testing random samples of people using antibody tests could help researchers to gain more knowledge in the fight against COVID-19. Such tests may also potentially be useful in determining who may have immunity against the virus, although it is not yet clear if the presence of antibodies against the virus causing COVID-19 indicates effective immunity.
Existing techniques to assess if an antibody is in the blood often rely on a visual assessment to determine whether a result is positive. This means that the accuracy is limited, as interpreting results is subject to human error. To address this, these researchers have developed a new type of microfluidic test, which is based on binding a fluorescently labelled protein to the antibody of interest in a serum sample.

The technique involves detecting the fluorescence polarization of the bound fluorescent molecules, and liquid crystal molecules are used to control the direction of this polarization. Once the sample is within the microfluidic device, it is then attached to a portable fluorescence polarization analyzer, weighing only 5.5 kg, which can measure the fluorescence signal and indicate if the antibody is present in the sample.

The researchers mix the serum sample with the fluorescent reagent and then allow it to rest for 15 minutes before loading it into the microfluidic device. They then attach the microfluidic device to the portable fluorescence polarization analyzer to obtain a reading. The entire process takes only 20 minutes, and such devices could help to speed up and streamline community testing for antibodies related to COVID-19, and allow for testing outside of medical labs.

“Our analyzer could be used to conduct other bio tests if suitable reagents are developed,” said Manabu Tokeshi, a researcher involved in the study. “By reproducing fragments of spike proteins expressed in the novel coronavirus, and using them as the reagent, the analyzer should be able to detect anti-coronavirus antibodies.”

Original news can be found at Medgadget

6 Predictions on how ultrasound systems market will expand through 2022

Due to the increasing adoption of advanced imaging systems in healthcare industry, ultrasound systems continue to be an irreplaceable commodity. In the view of rising healthcare costs, affordable and accurate imaging & diagnosis achieved through ultrasound technology will continue to attract patients, and render profits even in conventional medical settings.

The report on the global market for ultrasound systems projects a steady growth for the market during 2017-2022. The global ultrasound systems market, which is pegged to reach $6Bn by end-2017, will soar steadily at a 5.5% CAGR to reach $7.8Bn towards the end of 2022.

Following are key projections on the global ultrasound systems market, excerpted from the report:

The report highlights the application of ultrasound systems in cardiology. Alarming rise in incidence of cardiac disorders throughout the globe is expected to drive the adoption of ultrasound systems, which are effectively used in cardiology diagnostics. Between 2017 and 2022, more than US$ 430 Mn worth of incremental opportunity will be created by application of ultrasound systems in cardiology. The report also predicts that nearly half of ultrasound systems sold in the global market during the forecast period will be developed on 2D ultrasound imaging technology.

Healthcare infrastructure in developed economies such as the US and Canada is expected to promote the adoption of ultrasound systems. The report projects that by the end of 2022, North America’s ultrasound systems market will have reached an estimated value of US$ 3.2 Bn. During this forecast period, North America is also anticipated to be the largest market for ultrasound systems in the world.

The report also observes impressive growth in the ultrasound systems market across European countries. In 2017, more than 25% of the global ultrasound systems market value is expected to be accounted by sales of ultrasound systems in Europe.

Demand for ultrasound systems in the Asia-Pacific excluding Japan (APEJ) region is projected to be lower than above regions, however, manufacturers will be interested in laying down their production units in this region. In such manner, the APEJ ultrasound systems market is likely to account for more than 15% of the global market revenues throughout the forecast period.

Based on the portability of ultrasound systems, the report expects a higher demand for standalone systems. By procuring revenues worth $4.2Bn, standalone ultrasound systems will dominate the global market with more than 70% revenue share towards the end of 2017. On the other hand, portable ultrasound systems will showcase a robust revenue growth at 6.4% CAGR, albeit, reflecting a little over 17% share on the global ultrasound systems market.

Hospitals will remain the largest end-users of ultrasound systems in the global market, and account for half of its value in the years to come. Meanwhile, diagnostic centers will contribute to nearly 20% of the global ultrasound systems market, procuring revenues worth $1.6Bn by end-2022.

The report has profiled leading players in the global ultrasound systems market, which include companies namely, General Electric Company, Koninklijke Philips N.V., Toshiba Corporation, Siemens AG, Hitachi Ltd., Fujifilm Holdings Corporation, Esaote SpA., Shimadzu Corporation, Analogic Corporation, and Samsung Electronics Co. Ltd.

These insights are based on a report on Ultrasound Systems Market by Fact.MR
Original news can be found at: